APOBEC3B expression and its prognostic potential in breast cancer

Mao,Yan; Lv,Meng; Zhang,Yuzi; Nie,Gang; Cui,Jian; Wang,Yongmei; Wang,Yuanyuan; Cao,Weihong; Liu,Xiaoyi; Wang,Xingang; Wang,Haibo

doi:10.3892/ol.2020.11433

APOBEC3B expression and its prognostic potential in breast cancer

Authors:
- Yan Mao
- Meng Lv
- Yuzi Zhang
- Gang Nie
- Jian Cui
- Yongmei Wang
- Yuanyuan Wang
- Weihong Cao
- Xiaoyi Liu
- Xingang Wang
- Haibo Wang
View Affiliations

Affiliations: Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, 3D Medicines Inc., Shanghai 200025, P.R. China
Published online on: March 3, 2020 https://doi.org/10.3892/ol.2020.11433
Pages: 3205-3214
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) mRNA expression is associated with the poor prognosis of estrogen receptor positive (ER+) breast cancer. However, the clinical relevance of APOBEC3B protein expression in patients with breast cancer remains unclear. The present study evaluated the association of APOBEC3B protein expression with clinicopathological features, as well as survival outcomes of patients with breast cancer. Furthermore, the association between APOBEC3B protein expression and tumor infiltrating lymphocytes (TILs) was investigated. APOBEC3B protein expression in 120 patients with breast cancer was evaluated via immunohistochemistry, using a constructed tumor microarray, and TILs were analyzed by hematoxylin and eosin staining. The relevance of APOBEC3B mRNA expression in breast cancer was assessed using a Kaplan‑Meier Plotter online tool, as well as the Tumor Immune Estimation Response and The Cancer Genome Atlas databases. The present study assessed APOBEC3B expression in 116 patients with breast cancer and demonstrated that protein expression was significantly associated with ER and progesterone receptor expression, as well as different subtypes of breast cancer. Notably, APOEBC3B protein expression was significantly associated with TILs. Overall, high expression levels of APOBEC3B protein and high levels of TILs were indicative of longer disease‑free survival rate. High APOBEC3B mRNA expression was associated with poor relapse‑free survival rate, overall survival rate and distant metastasis‑free survival rate in patients with breast cancer, particularly for the Luminal A subtype. APOBEC3B mRNA expression was also indicated to be associated with the immune status of patients with breast cancer. Overall, the results of the present study demonstrated that APOBEC3B mRNA and protein expression levels presented different prognostic values in the survival of patients with breast cancer. However, both APOBEC3B mRNA and protein expression levels were associated with TILs in breast cancer. Therefore, APOBEC3B may be a prognostic biomarker for breast cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, et al: The landscape of cancer genes and mutational processes in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
5	Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al: Patterns of somatic mutation in human cancer genomes. Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI
6	Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al: Mutational processes molding the genomes of 21 breast cancers. Cell. 149:979–993. 2012. View Article : Google Scholar : PubMed/NCBI
7	Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, et al: Signatures of mutational processes in human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
9	Smith HC, Bennett RP, Kizilyer A, McDougall WM and Prohaska KM: Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol. 23:258–268. 2012. View Article : Google Scholar : PubMed/NCBI
10	Refsland EW and Harris RS: The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol. 371:1–27. 2013.PubMed/NCBI
11	Harris RS and Liddament MT: Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 4:868–877. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ng JCF, Quist J, Grigoriadis A, Malim MH and Fraternali F: Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. Nucleic Acids Res. 47:1178–1194. 2019. View Article : Google Scholar : PubMed/NCBI
13	Wang S, Jia M, He Z and Liu XS: APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 37:3924–3936. 2018. View Article : Google Scholar : PubMed/NCBI
14	Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, et al: Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res. 18:562016. View Article : Google Scholar : PubMed/NCBI
15	Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Refsland EW, Kotandeniya D, Tretyakova N, et al: APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494:366–370. 2013. View Article : Google Scholar : PubMed/NCBI
16	Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, et al: Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 48:1330–1338. 2016. View Article : Google Scholar : PubMed/NCBI
17	Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 45:970–976. 2013. View Article : Google Scholar : PubMed/NCBI
18	Harris RS: Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res. 17:82015. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Delahanty R, Guo X, Zheng W and Long J: Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer. Hum Genomics. 9:342015. View Article : Google Scholar : PubMed/NCBI
20	Kuong KJ and Loeb LA: APOBEC3B mutagenesis in cancer. Nat Genet. 45:964–965. 2013. View Article : Google Scholar : PubMed/NCBI
21	Kanu N, Cerone MA, Goh G, Zalmas LP, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, et al: DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 17:1852016. View Article : Google Scholar : PubMed/NCBI
22	Cescon DW, Haibe-Kains B and Mak TW: APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci USA. 112:2841–2846. 2015. View Article : Google Scholar : PubMed/NCBI
23	Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, et al: Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor positive breast cancers. Horm Cancer. 5:405–413. 2014. View Article : Google Scholar : PubMed/NCBI
24	Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, Yoshiyama S, Rokudai S, Odawara H, Tokiniwa H, Oyama T, et al: APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers. Breast Cancer. 23:780–788. 2016. View Article : Google Scholar : PubMed/NCBI
25	Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, et al: The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv. 2:e16017372016. View Article : Google Scholar : PubMed/NCBI
26	Rüder U, Denkert C, Kunze CA, Jank P, Lindner J, Jöhrens K, Kulbe H, Sehouli J, Dietel M, Braicu E and Darb-Esfahani S: APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. Histol Histopathol. 34:405–417. 2018.PubMed/NCBI
27	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC cancer staging manual. 7th. Springer (ed.); New York: pp. 345–376. 2010
28	Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, Tan X, Zhang Q, Liu Y, Zhu Y, et al: Gene expression profling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 63:1457–1467. 2014. View Article : Google Scholar : PubMed/NCBI
29	Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han Y, Liu Y, Yu ZQ, Zuo ZG, Xing JJ, et al: Expression of ZNF148 in diferent developing stages of colorectal cancer and its prognostic value: A large Chinese study based on tissue microarray. Cancer. 119:2212–2222. 2013. View Article : Google Scholar : PubMed/NCBI
30	Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015. View Article : Google Scholar : PubMed/NCBI
31	Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
32	Du Y, Tao X, Wu J, Yu H, Yu Y and Zhao H: APOBEC3B up-regulation independently predicts ovarian cancer prognosis: A cohort study. Cancer Cell Int. 18:782018. View Article : Google Scholar : PubMed/NCBI
33	Fujiki Y, Yamamoto Y, Sueta A, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Tomiguchi M, Takeshita T and Iwase H: APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer. Oncotarget. 9:30513–30526. 2018. View Article : Google Scholar : PubMed/NCBI
34	Mao Y, Qu Q, Chen X, Huang O, Wu J and Shen K: The Prognostic value of tumor-infiltrating lymphocytes in breast cancer: A Systematic review and meta-analysis. PLoS One. 11:e01525002016. View Article : Google Scholar : PubMed/NCBI
35	Mao Y, Qu Q, Zhang Y, Liu J, Chen X and Shen K: The value of tumor infiltrating lymphocytes for predicting response to neoadjuvant chemotherapy in breast cancer: A systemic review and meta-analysis. PLoS One. 9:e01151032014. View Article : Google Scholar